Andra AP fonden Purchases 16,900 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Andra AP fonden boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 63.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 43,400 shares of the biopharmaceutical company’s stock after purchasing an additional 16,900 shares during the quarter. Regeneron Pharmaceuticals comprises about 0.8% of Andra AP fonden’s holdings, making the stock its 16th biggest holding. Andra AP fonden’s holdings in Regeneron Pharmaceuticals were worth $45,615,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. SteelPeak Wealth LLC increased its holdings in Regeneron Pharmaceuticals by 173.0% in the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after buying an additional 692 shares in the last quarter. Atria Investments Inc grew its stake in shares of Regeneron Pharmaceuticals by 12.2% in the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after acquiring an additional 941 shares during the period. Nordea Investment Management AB raised its holdings in shares of Regeneron Pharmaceuticals by 23.2% during the first quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after purchasing an additional 5,495 shares during the last quarter. Tidal Investments LLC increased its position in Regeneron Pharmaceuticals by 16.8% during the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after acquiring an additional 711 shares during the last quarter. Finally, Sierra Summit Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $1,011,000. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now owns 17,882 shares in the company, valued at $18,941,329.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,561 shares of company stock valued at $13,095,105. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.2 %

Shares of NASDAQ REGN opened at $1,144.77 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The stock has a market capitalization of $126.20 billion, a P/E ratio of 33.82, a price-to-earnings-growth ratio of 3.86 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The business has a fifty day moving average price of $1,114.85 and a 200 day moving average price of $1,021.92.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the business earned $8.79 EPS. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on REGN shares. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, September 2nd. Piper Sandler increased their price objective on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Barclays raised their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,109.70.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.